Condition
Grass Allergy
Total Trials
7
Recruiting
0
Active
0
Completed
6
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 7 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
14%
1 trials in Phase 3/4
Results Transparency
0%
0 of 6 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 2 (2)
P 3 (1)
Trial Status
Completed6
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (7)
Showing 7 of 7 trials
NCT02965612Not ApplicableUnknown
Specific Immunotherapy for Allergic Child
NCT02075138CompletedPrimary
Grass Observational Study
NCT02292875Completed
ToleroMune Grass Follow on Study
NCT01923779CompletedPrimary
ToleroMune Grass Follow on Study
NCT01385800Phase 2CompletedPrimary
ToleroMune Grass Exposure Unit Study
NCT01728285Phase 3Completed
Compliance to the Treatment With GRAZAX® Tablets in Patients With Seasonal Grass Pollen Rhinoconjunctivitis
NCT01123252Phase 2Completed
Seasonal Allergic Rhinitis Study
Showing all 7 trials